<p>Antimicrobial drug resistance poses a global health challenge that necessitates the identification of new druggable targets<sup><CitationRef AdditionalCitationIDS="CR2" CitationID="CR1">1</CitationRef>–<CitationRef CitationID="CR3">3</CitationRef></sup>. The essential lipid II flippase MurJ is a promising yet underexplored antimicrobial target in bacterial cell wall biosynthesis<sup><CitationRef AdditionalCitationIDS="CR5 CR6" CitationID="CR4">4</CitationRef>–<CitationRef CitationID="CR7">7</CitationRef></sup>. The only known inhibitors of Gram-negative (diderm) MurJ are the single-gene lysis proteins (Sgls) from the lytic single-strand RNA phages M (Sgl<sup>M</sup>) and PP7 (Sgl<sup>PP7</sup>)<sup><CitationRef CitationID="CR8">8</CitationRef>,<CitationRef CitationID="CR9">9</CitationRef></sup>. Sgl<sup>M</sup> and Sgl<sup>PP7</sup> have distinct evolutionary origins and share no sequence similarity. Here we describe a common mechanism of MurJ inhibition by these phage-encoded Sgls. We determined the structures of MurJ-bound Sgl<sup>M</sup> and Sgl<sup>PP7</sup> and discovered a third distinct MurJ-targeting Sgl from the predicted phage Changjiang3 (Sgl<sup>CJ3</sup>) that we also characterized structurally. Our findings demonstrate that all three Sgls evolved convergently to trap MurJ in a periplasm-open conformation through a common MurJ interface, revealing a pathway for drug design.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Convergent MurJ flippase inhibition by phage lysis proteins

  • Yancheng E. Li,
  • S. Francesca Antillon,
  • Grace F. Baron,
  • Karthik Chamakura,
  • Ry Young,
  • William M. Clemons Jr

摘要

Antimicrobial drug resistance poses a global health challenge that necessitates the identification of new druggable targets13. The essential lipid II flippase MurJ is a promising yet underexplored antimicrobial target in bacterial cell wall biosynthesis47. The only known inhibitors of Gram-negative (diderm) MurJ are the single-gene lysis proteins (Sgls) from the lytic single-strand RNA phages M (SglM) and PP7 (SglPP7)8,9. SglM and SglPP7 have distinct evolutionary origins and share no sequence similarity. Here we describe a common mechanism of MurJ inhibition by these phage-encoded Sgls. We determined the structures of MurJ-bound SglM and SglPP7 and discovered a third distinct MurJ-targeting Sgl from the predicted phage Changjiang3 (SglCJ3) that we also characterized structurally. Our findings demonstrate that all three Sgls evolved convergently to trap MurJ in a periplasm-open conformation through a common MurJ interface, revealing a pathway for drug design.